UBS analyst Ashwani Verma lowered the price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $24.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE